RELMADA THERAPEUTICS, INC. (RLMD) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 28.59M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 8.74M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -65.13M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $28.59M | (m) | $8.74M | $-65.13M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $23.02M | (m) | $11.29M | $-60.34M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $26.88M | (m) | $13.91M | $-59.10M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $29.81M | (m) | $18.26M | $-57.84M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $36.92M | (m) | $22.60M | $-70.52M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $44.82M | (m) | $26.37M | $-79.12M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $46.18M | (m) | $30.18M | $-83.89M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $49.93M | (m) | $33.35M | $-91.64M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $49.23M | (m) | $36.80M | $-91.33M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $52.25M | (m) | $40.75M | $-98.54M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $54.81M | (m) | $43.81M | $-103.70M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $-21.39M | (m) | $45.54M | $7.38M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $-1.31M | (m) | $42.49M | $-8.67M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $15.86M | (m) | $43.62M | $-28.15M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $113.32M | (m) | $44.19M | $-161.25M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $111.73M | (m) | $50.93M | $-156.73M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $115.19M | (m) | $50.60M | $-160.65M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $101.61M | (m) | $46.57M | $-141.60M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $90.62M | (m) | $40.49M | $-125.70M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $80.25M | (m) | $25.32M | $-112.44M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $57.49M | (m) | $22.56M | $-86.97M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $45.49M | (m) | $21.59M | $-73.27M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $35.97M | (m) | $20.78M | $-60.84M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $22.70M | (m) | $19.20M | $-44.48M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $13.35M | (m) | $14.71M | $-31.00M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $7.86M | (m) | $3.17M | $-15.11M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $7.49M | (m) | $1.82M | $-14.02M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $7.02M | (m) | $1.21M | $-12.73M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $4.91M | (m) | $963.36K | $-10.52M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $5.31M | (m) | $730.93K | $-10.37M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $4.20M | (m) | $601.93K | $-8.35M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $2.94M | (m) | $518.00K | $-6.92M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $2.17M | (m) | $657.04K | $-6.77M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $991.71K | (m) | $603.34K | $-6.50M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $1.10M | (m) | $601.26K | $-6.58M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $1.29M | (m) | $704.45K | $-7.22M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $1.72M | (m) | $567.40K | $-8.54M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $1.84M | (m) | $735.39K | $-9.02M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $3.71M | (m) | $891.14K | $-13.20M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $6.21M | (m) | $1.00M | $-16.22M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $8.46M | (m) | $1.04M | $-17.52M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $10.05M | (m) | $1.01M | $-19.34M | $3.37K | (m) | (m) | -5739.98× | Reported |
| 2015-09-30 | $10.02M | (m) | $922.47K | $-18.01M | $3.30K | (m) | (m) | -5463.08× | Reported |
| 2015-06-30 | $7.87M | (m) | $796.95K | $-17.10M | $4.92K | (m) | (m) | -3474.05× | Reported |
| 2015-03-31 | $-5.71M | (m) | $10.85M | $-24.91M | $316.30K | (m) | (m) | -78.75× | Reported |
| 2014-12-31 | $-3.65M | (m) | $10.68M | $-21.05M | $439.98K | (m) | (m) | -47.85× | Reported |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | $-5.13M | (m) | $434.39K | $-6.88M | $314.69K | (m) | (m) | -21.88× | Reported |
| 2014-02-28 | (m) | $3.17K | (m) | $-49.35K | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-5.25M | (m) | $382.34K | $-6.77M | $220.31K | (m) | (m) | -30.75× | Reported |
| 2013-11-30 | (m) | $4.83K | (m) | $-50.37K | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-08-31 | (m) | $5.13K | (m) | $-45.02K | (m) | (m) | (m) | (m) | (m) |
| 2013-05-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-02-28 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $-667.47K | (m) | $37.34K | $-3.16M | $27.72K | (m) | (m) | -113.87× | Reported |
| 2012-11-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-08-31 | (m) | $7.94K | (m) | $-12.05K | (m) | (m) | (m) | (m) | (m) |
| 2012-05-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-02-29 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |